• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NeoStem Announces Opening of Las Vegas Adult Stem Cell Collection Center and Further Market Penetration in Western United States

Posted on: Wednesday, 10 October 2007, 09:00 CDT

NeoStem, Inc. (AMEX:NBS), a leading-edge biotechnology services company capitalizing on breakthroughs in the burgeoning field of adult stem cell therapeutics, has announced that the newest adult stem cell collection facility in its network has opened in Las Vegas, Nevada. The opening of the new Las Vegas center signals the latest successful milestone in the Company's business strategy to establish a nationwide network of specialized adult stem cell facilities.

The Las Vegas location offers a number of strategic advantages for NeoStem, including an extremely high level of potential customer traffic (for both U.S. and international travelers) and an exciting destination center for customers seeking a simple yet powerful way to protect their long-term health.

The new facility will provide NeoStem's proprietary procedures and technology to enable the collection of adult stem cells for one's own future therapeutic use in times of critical medical need. The cells collected are considered "autologous," as they are used by the donor exclusively for personal use to ensure biocompatibility.

"NeoStem continues to follow through on its high-growth business model focused on expanding its collection center network to major consumer centers around the globe," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "We're excited to announce the opening of the new facility and to extend our leadership in making this powerful medical technology available to the public as researchers develop breakthrough cures and therapies to many debilitating conditions. By continuing to execute on our business plan we're positioned to capitalize effectively and profitably on new developments in adult stem cell science."

Prospective clients for the new Las Vegas facility include anyone concerned with their long-term health, well-being or risk of radiation exposure. Currently, adult stem cells are at the core of hundreds of research studies at medical and academic institutions seeking to develop breakthrough therapies and cures for a broad range of humankind's most serious diseases, including diabetes, heart disease, multiple sclerosis, lymphoma and other cancers, and other conditions.

"I believe that both local residents, as well as tourists from around the world, will be inclined to bank their stem cells for their future personal use with the same enthusiasm as they would demonstrate at the gaming tables in a casino. However, the odds are far greater that you will eventually be a winner having your stem cells banked," remarked Dr. Ivan Goldsmith, the facility's Medical Director and well known Las Vegas physician.

"NeoStem is the only company making available adult stem cell collection and storage services to the medical community for an individual's own potential future use," said Dr. Robin Smith. "Physicians across the nation have expressed the strong desire to provide such services to their patients and we are in talks with several medical groups to expand our network."

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one's future health.

The Company's business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: www.neostem.com.

For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.

Source: Business Wire

More News in this Category